Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D02KAW
|
||||
Former ID |
DNCL001700
|
||||
Drug Name |
CDP-7657
|
||||
Synonyms |
CD40L
|
||||
Drug Type |
Antibody
|
||||
Indication | Systemic lupus erythematosus [ICD9: 710; ICD10:M32] | Phase 1 | [522990] | ||
Company |
Biogen Idec
|
||||
Target and Pathway | |||||
Target(s) | Tumor necrosis factor ligand superfamily member 5 | Target Info | [533182], [533313] | ||
KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
NF-kappa B signaling pathway | |||||
Cell adhesion molecules (CAMs) | |||||
T cell receptor signaling pathway | |||||
Intestinal immune network for IgA production | |||||
Malaria | |||||
Toxoplasmosis | |||||
Asthma | |||||
Autoimmune thyroid disease | |||||
Systemic lupus erythematosus | |||||
Allograft rejection | |||||
Primary immunodeficiency | |||||
Viral myocarditis | |||||
References | |||||
Ref 533182 | First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus. Lupus. 2015 Sep;24(10):1045-56. | ||||
Ref 533313 | CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study. Arthritis Res Ther. 2015 Sep 3;17:234. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.